

M

*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Macitentan (Opsumit®) (952/14)	Long-term treatment of pulmonary arterial hypertension in adults	Restricted to initiation and supply by specialists working in the Scottish Pulmonary Vascular Unit, Glasgow	137	Apr/May 2014
Macrogol 3500 (Movicol® Paediatric Plain)	Paediatric faecal impaction		41	2004
Macrogol 4000 (Idrolax®)	Constipation		38	2004
Magnesium aspartate dihydrate (Magnaspartate®) (1042/15)	For the treatment and prevention of magnesium deficiency, as diagnosed by a doctor	Formulary	150	June 2015
Magnesium glycerophosphate 4mmol chewable tablet (Neomag®) SMC No. (1267/17)	As an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.	Available in line with national guidance	164	Oct 2017
Mannitol 400mg, inhalation powder, hard capsule (Bronchitol®) (837/13)	Treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.	Non-formulary - alternatives preferred	134 133 125	Jan/Feb 2014 Dec 13/Jan 14 Mar/Apr 2013
Maraviroc 20mg/mL oral solution,	In combination with other antiretroviral medicinal products for	Not available as not	164	Nov 2017

25mg, 75mg, 150mg and 300mg film-coated tablets (Celsentri®) SMC No (1282/17)	treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable.	recommended for use in NHS Scotland		
Maraviroc (Celsentri®) (458/08)	CCR5-tropic HIV-1 infection	Not recommended	83 78	Oct 2008 Apr 2008
Maribavir film-coated tablets (Livtency®) SMC2576	treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Mavacamten hard capsules (Camzyos) SMC2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197	May 2024
Mecasermin solution for injection (Increlex®) (563/09)	Growth factor-1 deficiency (primary IGFD)	HOSPITAL ONLY Non-formulary	92	Aug/Sept 2009
Medroxyprogesterone acetate (Sayana® Press) (896/13)	Long-term female contraception	Formulary (Restricted to patients with I.M. injection inappropriate)	130	Sept/Oct 2013
Melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) SMC2306	<p>Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.</p> <p>Melatonin prolonged-release (Slenyto®), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep problems and autism</p>	Not available as not recommended for use in NHS Scotland	183	March 2021

	spectrum disorder and / or Smith-Magenis syndrome who had an insufficient response to sleep hygiene measures.			
Melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) SMC2168	Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient		177	Dec 2019
Melatonin 2mg prolonged-release tablets (Circadin®) (500/08)	Primary insomnia	Not recommended	82	Aug/Sept 2008
Memantine (Ebixa®) (57/03)	Alzheimer's disease	GPs may prescribe under the direction of Psychiatry of Old Age (Dundee & Angus)	110 35 29	Oct 2011 2004 2003
Mepolizumab 100mg powder for solution for injection (Nucala®) SMC2139	As an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10 ⁹ /L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids	Available in line with national guidance. Hospital only: Paediatric respiratory clinic.	174	May 2019
Mepolizumab (Nucala®)(1149/16)	As an add-on treatment for severe refractory eosinophilic asthma in adult patients. Restriction: patients who have had eosinophils of at least 150 cells per microlitre (0.15 x 10 ⁹)/L at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.	Available in line with local guidance for prescribing	156 157	Sep 2016 Nov 2016
Mercaptamine gastro-resistant hard capsules (Procysbi®) SMC2571	treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	Not available as not recommended for use in NHS Scotland	195	December 2023
Mercaptamine 25mg and 75mg (as bitartrate) gastro-resistant	For the treatment of proven nephropathic cystinosis. A phase III, open-label, crossover study demonstrated that			

hard capsules (Procysbi®) SMC2374	extended-release mercaptamine (Procysbi®) was non-inferior to immediate-release mercaptamine in control of white blood cell cystine levels in patients with nephropathic cystinosis who were previously controlled on mercaptamine therapy. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.			
Mercaptamine 25mg and 75mg (as bitartrate) gastro-resistant hard capsules (Procysbi®) SMC2374	Indication under review: For the treatment of proven nephropathic cystinosis. A phase III, open-label, crossover study demonstrated that extended-release mercaptamine (Procysbi®) was non-inferior to immediate-release mercaptamine in control of white blood cell cystine levels in patients with nephropathic cystinosis who were previously controlled on mercaptamine therapy. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	187	Dec 2021
Mercaptamine, 25mg and 75mg (as bitartrate), gastro-resistant hard capsules (Procysbi®) SMC No (1272/17)	For the treatment of proven nephropathic cystinosis	Not available as not recommended for use in NHS Scotland	165	Jan 2018
Mercaptopurine (Xaluprine®) (798/12)	Treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children	HOSPITAL ONLY (Paediatrics)	119	Aug/Sept 2012
Meropenem/vaborbactam 1 gram/1 gram powder for concentrate for solution for infusion (Vaborem®) SMC2278	For the treatment of the following infections in adults: • Complicated urinary tract infection (cUTI), including pyelonephritis • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in	Available in line with local guidance for prescribing alert antibiotic guidance	181	November 2020

	<p>association with, or is suspected to be associated with, any of the infections listed above.</p> <p>Meropenem/vaborbactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.</p> <p>SMC restriction: for adults with confirmed carbapenem-resistant Enterobacteriaceae (CRE), which is involved in the production of Klebsiella pneumoniae carbapenemase (KPC) associated with cUTI (including acute pyelonephritis [AP]), cIAI, HAP (including VAP) and bacteraemia that occurs in association with, or is suspected to be associated with any of the infections previously mentioned. Use should be on the advice of local microbiologists or specialists in infectious disease.</p> <p>In a randomised, double-blind, phase III study, meropenem/vaborbactam was non-inferior to a beta-lactamase/beta-lactamase inhibitor for the treatment of adults with cUTI, including AP. A smaller, randomised, open-label, phase III study suggested that meropenem/vaborbactam compared favourably with best available therapy for the treatment of adults with infections due to confirmed/suspected CRE.</p>			
Mesalazine (Asacol®) (222/05)	Moderate acute exacerbations of ulcerative colitis	Formulary	77	Mar 2008
Mesalazine (Asacol®) (223/05)	Mild acute exacerbations of ulcerative colitis	Formulary	77	Mar 2008
Mesalazine (Asacol®) (224/05)	Maintenance of remission in ulcerative colitis and Crohn's ilio-colitis	Formulary	77	Mar 2008
Mesalazine (Asacol®) (445/08)	Induction and maintenance of remission in mild to moderate ulcerative colitis	Non-formulary	77	Mar 2008
Metformin hydrochloride 500mg, 750mg and 1000mg prolonged release tablets (Glucophage SR®) SMC No 1308/18	Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are:	Not available as not recommended for use in NHS Scotland	167	April 2018

	<ul style="list-style-type: none"> • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months. 			
Metformin (Glucophage®) - powder for oral solution (610/10)	Type 2 diabetes mellitus	Non-formulary	96	Apr/May 2010
Metformin (Glucophage SR®)	Type 2 diabetes mellitus		98 93 55 49	Aug/Sept 2010 Oct/Nov 2009 2006 2005
Methotrexate solution for injection pre-filled syringe (Metoject®) (724/11)	Severe active juvenile idiopathic arthritis	HOSPITAL ONLY (Paediatric Rheumatology Clinic)	110 109	Oct 2011 Sept 2011
Methotrexate injection pre-filled syringe (Metoject®) (573/09)	Severe recalcitrant disabling psoriasis and severe psoriatic arthritis in adults	GPs may prescribe under the direction of Dermatology-Rheumatology Clinic	127 101 93	May 2013 Dec 10/Jan 2011 Oct/Nov 2009
Metreleptin powder for solution for injection (Myalepta®) SMC2559	An adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy	Available in line with national guidance	194	September 2023
Methotrexate injection (Metoject®) (332/06)	Severe active rheumatoid arthritis in adults	GPs may prescribe under the direction of the Rheumatology Clinic	127 65 64	May 2013 Jan 2007 2006
Methoxy polyethylene glycol-epoetin beta (Mircera®) (455/08)	Anaemia associated with chronic kidney disease (CKD)	HOSPITAL ONLY (Renal Clinic)	78	Apr 2008
Methyl aminolevulinate (Metvix®)	Actinic kerarosis	HOSPITAL ONLY (Dermatology Clinic)	33 28	2003

Methyl aminolevulinate (Metvix®)	Basal cell carcinoma		33 28	2003
Methylnaltrexone solution (Relistor®) (518/08)	Opioid-induced constipation	GPs may prescribe under the direction of Palliative Care - Contact local palliative care services for further advice	107 85	July 2011 Dec 2008
Methylphenidate ((Medikinet XL®) (388/07)	ADHD		71	July 2007
Methylphenidate (Equasym XL®)	ADHD		50	2005
Methylphenidate OROS (Concerta® XL)	ADHD		21	2002
Mexiletine 167mg hard capsules (Namuscla®) SMC2241	For the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Mexiletine 167mg hard capsules (Namuscla®) - SMC 2241	For the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. In a short-term, phase III, crossover study, mexiletine significantly improved muscle stiffness compared with placebo when measured on a visual analogue scale. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC	Not available as not recommended for use in NHS Scotland	180	Sept 2020
Micafungin powder (Mycamine®) (497/08)	Invasive candidiasis	Not recommended	85 82	Dec 2008 Aug/Sept 2008
Miconazole muco-adhesive	Oropharyngeal candidiasis	Not recommended	103	Feb/Mar

buccal (Loramyc®) (517/08)			85	2011 Dec 2008
Micronised progesterone 100mg capsules (Utrogestan®) SMC2529	For adjunctive use with oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT).	Available in line with local guidance for prescribing	192	Apr 23
Micronised progesterone, vaginal capsules 200mg (Utrogestan®) SMC No (935/13)	In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles	Available in line with national guidance	133 162	Dec 13/Jan 14 Aug 2017
Micronised progesterone (Utrogestan®) (542/09)	HRT	Not recommended	88	Apr 2009
Midazolam 2mg/mL oral solution in single-dose container (Ozalin®) SMC2392	In children from 6 months to 17 years old, for moderate sedation before a therapeutic or diagnostic procedure or as premedication before anaesthesia. Ozalin® 2mg/mL oral solution is supplied in single-use glass ampoules and the dose must be measured using the oral applicator, which is graduated in kg of body weight, and the filter straw provided. The availability of midazolam oral solution (Ozalin®) provides a licensed alternative to an unlicensed preparation.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for other medicines	187	Awaiting publication
Midazolam (as maleate) 10mg/1mL oromucosal solution prefilled syringe (Epistatus® PFS) SMC No 1279/17	Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.	Available in line with National Guidance	165	Jan 2018
Midazolam (Buccolam®) (757/12)	Prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years)	Non-formulary - alternatives preferred	116 115	Apr/May 2012 Mar/Apr 2012
Midodrine hydrochloride	For use in adults for the treatment of severe orthostatic	Non-formulary - pending local	152	Nov/Dec

(Bramox®) (1094/15)	hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.	protocol under development		2015
Midostaurin 25mg soft capsules (Rydapt®) SMC2100	As monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Midostaurin 25mg soft capsules (Rydapt®) SMC No 1330/18	In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult	Not recommended.	169	July 2018
Mifamurtide (Mepact®) (621/10)	High-grade resectable non-metastatic osteosarcoma	HOSPITAL ONLY (Paediatric Department - under the direction of tertiary centre)	110 109 97	Oct 2011 Sept 2011 June/Jul 2010
Mifepristone (Medabon®) (913/13)	For medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea	Formulary HOSPITAL ONLY	143	Nov/Dec 2014
Migalastat 123mg hard capsules (Galafold®) SMC 1196/16	Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α -galactosidase A deficiency) and who have an amenable mutation. SMC restriction: in males with classic mutations (leucocyte enzyme activity <1%) treatment should commence at diagnosis; in females and those males with later onset mutations with higher levels of leucocyte enzyme activity, treatment should commence when patients experience uncontrolled pain, evidence of renal, cardiac or neurovascular disease, or gastrointestinal symptoms that significantly reduce quality of life	Available in line with National guidance – Hospital use only	158 160	Dec 2016 Apr 2017
Miglustat (Zavesca®)	Progressive neurological manifestations in adults and paediatric patients with Niemann-Pick type C disease	Not recommended	97	June/Jul 2010

Miglustat (Zavesca®)	Gaucher disease		47	2004
Mirabegron (Betmiga®) (862/13)	Overactive bladder (OAB) syndrome	Formulary	127	May 2013
Mirtazapine (Zispin SolTab®)	Depressive illness		36 32	2003
Mirkizumab solution for injection in pre-filled pen and concentrate for solution for infusion (Omvoh®) SMC 2650	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197	May 2024
Misoprostol (Mysodelle®) (996/14)	Induction of labour in women with an unfavourable cervix from 36 weeks gestation	Non-formulary - absence of clinician demand	142	Oct/Nov 2014
Mitotane (Lysodren®)	Advanced adrenal cortical carcinoma		64	2006
Mobocertinib 40mg hard capsules (Exkivity®) SMC2516	As monotherapy for the treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior platinum-based chemotherapy. In a single-arm, phase I/II study, 28% of patients previously treated with platinum-based chemotherapy with EGFR exon 20 insertion mutation-positive metastatic NSCLC achieved a confirmed objective response.	Available in line with national guidance	192	April 2023
Modafinil (Provigil®) Indication discontinued Feb 2011	Obstructive sleep apnoea/hypopnoea	Discontinued	52 32 56	2005 2003 2006
Modafinil (Provigil®) Indication discontinued Feb 2011	Shift work sleep disorder	Discontinued	52	2005
Mogamulizumab 4mg/ml concentrate for solution for	Treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior	Available in line with national guidance	185	July 2021

infusion (Poteligeo®) SMC2336	systemic therapy. SMC restriction: for the treatment of patients with advanced MF or SS (stage ≥IIB MF and all SS) following at least one prior systemic therapy, who are clinically ineligible for or refractory to treatment with brentuximab vedotin.			
Momelotinib film coated tablet (Omijara) SMC2636	Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Available in line with national guidance	198 not yet published	
Mometasone (Asmanex Twisthaler®)	Asthma		36 33	2003
Montelukast (Singulair®)	Symptomatic relief of SAR in adults with co-morbid asthma		52	2005
Montelukast paediatric granules (Singulair®) (383/07)	Asthma	Formulary (ENT specialist list)	112 71 43	Dec 2011 July 2007 2004
Mosunetuzumab concentrate for solution for infusion (Lunsumio®) SMC2542	as monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.	Not available as not recommended for use in NHS Scotland	195	December 2023
Moxifloxacin (Avelox®) (650/10)	Community acquired pneumonia	Non-formulary	102 101 37 32	Jan/Feb 2011 Dec 10/Jan 2011 2003
Moxifloxacin (Avelox®)	Acute exacerbation of chronic bronchitis		37 32	2003
Mycophenolic acid (Myfortic®)	Prophylaxis of transplant rejection		115 48	Mar/Apr 2012 2005

Updated: 26th August 2024

[Back to top](#)

[Back to homepage](#)